Market open
Pyxis Oncology/$PYXS
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Pyxis Oncology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Ticker
$PYXS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
44
ISIN
US7473241013
Website
Pyxis Oncology Metrics
BasicAdvanced
$69M
-
-$1.57
-
-
Price and volume
Market cap
$69M
52-week high
$4.61
52-week low
$0.83
Average daily volume
524K
Financial strength
Current ratio
7.753
Quick ratio
7.306
Long term debt to equity
17.782
Total debt to equity
19.245
Management effectiveness
Return on assets (TTM)
-29.19%
Return on equity (TTM)
-66.30%
Valuation
Price to book
0.66
Price to tangible book (TTM)
0.67
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
19.25%
3-year earnings per share growth (CAGR)
-28.76%
What the Analysts think about Pyxis Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pyxis Oncology stock.
Pyxis Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Pyxis Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Pyxis Oncology News
AllArticlesVideos
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·1 day ago
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewsWire·2 days ago
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pyxis Oncology stock?
Pyxis Oncology (PYXS) has a market cap of $69M as of May 16, 2025.
What is the P/E ratio for Pyxis Oncology stock?
The price to earnings (P/E) ratio for Pyxis Oncology (PYXS) stock is 0 as of May 16, 2025.
Does Pyxis Oncology stock pay dividends?
No, Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Pyxis Oncology dividend payment date?
Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pyxis Oncology?
Pyxis Oncology (PYXS) does not currently have a Beta indicator.